The impact of tacrolimus on growth factors in experimental proliferative vitreoretinopathy

Retina

Volumn 32, Issue 2, 2012, Pages 232-241

  Turgut, Burak ^a   Uyar, Fatma ^a   Ustundag, Bilal ^a   Celiker, Ulku ^a   Akpolat, Nusret ^a   Demir, Tamer ^a  

^a FIRAT UNIVERSITY   (Turkey)

Author keywords

fibroblast growth factor; platelet derived growth factor; proliferative vitreoretinopathy; tacrolimus; transforming growth factor

Indexed keywords

FIBROBLAST GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENUCLEATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL GUINEA PIG; HISTOPATHOLOGY; NONHUMAN; PATHOGENESIS; PHOTORECEPTOR CELL; RETINA; TREATMENT RESPONSE; VITREORETINOPATHY;

ANIMALS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLAST GROWTH FACTOR 2; GUINEA PIGS; IMMUNOSUPPRESSIVE AGENTS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTRAVITREAL INJECTIONS; PLATELET-DERIVED GROWTH FACTOR; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; VITREORETINOPATHY, PROLIFERATIVE;

EID: 84856591813     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31821e2207     Document Type: Article

References (61)

1. Peyman GA, Schulman JA. Intravitreal Surgery. 2nd ed. Upper Saddle River, NJ: Prentice Hall International Inc; 1994.
2. Charteris DG. Proliferative vitreoretinopathy: pathobiology, surgical management and adjunctive treatment. Br J Oph-thalmol 1995;79:953-960.
3. Machemer R, Sugita G, Tano Y. Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc 1979;77:171-180. (Pubitemid 10072805)
4. Charteris DG, Sethi CS, Lewis GP, et al. Proliferative vitreoretinopathy developments in adjunctive treatment and retinal pathology. Eye 2002;16:369-374. (Pubitemid 34845964)
5. Lewis H, Aaberg TM, Abrams GW. Causes of failure after initial vitreoretinal surgery for severe proliferative vitreoretin-opathy. Am J Ophthalmol 1991;111:8-14.
6. Glaser BM, Lemor M. Pathobiology of Proliferative Vitreor-etinopathy. In: Ryan SJ, ed. Retina. 2nd ed. St Louis, MO: Mosby, 1994:2249-2263.
7. Pastor JC, de la Rua ER, Martin F. Proliferative vitreoretin-opathy: risk factors and pathobiology. Prog Retin Eye Res 2002;21:127-144. (Pubitemid 34242710)
8. Miyata S, Ohkuba Y, Mutoh S. A review of the action of tacrolimus (FK506) on experimental models of rheumatoid arthritis. Inflamm Res 2005;54:1-9. (Pubitemid 40385335)
9. Morikawa K, Oseko F, Morikowa S. The distinct effects of FK506 on the activation, proliferation, and differentiation of human B lymphocytes. Transplantation 1992;54: 1025-1030. (Pubitemid 23005540)
10. Walgenbach KJ, Kalff JC, Sonmez-Alpan E, et al. Upregula-tion of basic fibroblast growth factor during chronic rejection of rat intestinal allografts and its downregulation by FK 506. Transplant Proc 1998;30:2587. (Pubitemid 28459754)
11. Lopez-Ilasaca M, Schiene C, Küllertz G, et al. Effects of FK506-binding protein 12 and FK506 on autophosphorylation of epidermal growth factor receptor. J Biol Chem 1998;273:9430-9434. (Pubitemid 28183024)
12. Sengoku T, Kishi S, Sakuma S, et al. FK506 inhibition of histamine release and cytokine production by mast cells and basophils. Int J Immunopharmacol 2000;22:189-201. (Pubitemid 30102265)
13. Savikko J, Taskinen E, Von Willebrand E. Tacrolimus inhibits platelet-derived growth factor ligand and receptor induction as well as rejection changes in rat renal allografts during longterm follow-up. Transplant Proc 2002;34:1382.
14. Sasakawa T, Sasakawa Y, Ohkuba Y, et al. FK506 inhibits prostaglandin E2 production from synovial cells by suppressing peripheral blood mononuclear cells. Int Immunopharmacol 2005;5:1291-1297. (Pubitemid 40725722)
15. Migita K, Maeda Y, Abiru S, et al. Immunosuppressant FK506 inhibits matrix metalloproteinase-9 induction in TNF-alpha-stimulated human hepatic stellate cells. Life Sci 2006;78: 2510-2515.
16. Migita K, Miyashita T, Maeda Y, et al. FK506 suppresses the stimulation of matrix metalloproteinase 13 synthesis by interleukin-1beta in rheumatoid synovial fibroblasts. Immunol Lett 2005;98:194-199. (Pubitemid 40602630)
17. Sakuma S, Kato Y, Nishigaki F, et al. FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells. Br J Pharmacol 2000;130:1655-1663. (Pubitemid 30611945)
18. Sakuma S, Kato Y, Nishigaki F, et al. Effects of FK506 and other immunosuppressive anti-rheumatic agents on T cell activation mediated IL-6 and IgM production in vitro. Int Immunopharmacol 2001;1:749-757. (Pubitemid 32206535)
19. Kong X, Lin Z, Caro J. Immunophilin-ligands FK506 and CsA inhibit HIF1a expression by a VHL- and ubiquitin-independent mechanism. FEBS Lett 2006;580:6182-6186. (Pubitemid 44666802)
20. Lan CC, Yu HS, Wu CS, et al. FK506 inhibits tumour necrosis factor-alpha secretion in human keratinocytes via regulation of nuclear factor kappa B. Br J Dermatol 2005;153:725-732.
21. Kohyama T, Takizawa H, Kawasaki S, et al. A potent immunosuppressant FK506 inhibits IL-8 expression in human eosinophils. Mol Cell Biol Res Commun 1999;1:72-77. (Pubitemid 129532296)
22. Cho ML, Cho CS, Min SY, et al. Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblasts. Arthritis Rheum 2002;46:1202-1209.
23. Jorissen RN, Walker F, Pouliot N, et al. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003;284:31-53. (Pubitemid 36331965)
24. Dinbergs ID, Brown L, Edelman ER. Cellular response to transforming growth factor-beta1 and basic fibroblast growth factor depends on release kinetics and extracellular matrix interactions. J Biol Chem 1996;271:29822- 29829. (Pubitemid 26389613)
25. Wilson SE, Schultz GS, Chegini N, et al. Epidermal growth factor, transforming growth factor alpha, transforming growth factor beta, acidic fibroblast growth factor, basic fibroblast growth factor, and interleukin-1 proteins in the cornea. Exp Eye Res 1994;59:63-72. (Pubitemid 124011132)
26. Imanishi J, Kamiyama K, Iguchi I, et al. Growth factors: importance in wound healing and maintenance of transparency of the cornea. Prog Retin Eye Res 2000;19:113-129.
27. Honma Y, Nishida K, Sotozono C, et al. Effect of transforming growth factor-beta 1 and -beta 2 on in vitro rabbit corneal epithelial cell proliferation promoted by epidermal growth factor, keratinocyte growth factor, or hepatocyte growth factor. Exp Eye Res 1997;65:391-396. (Pubitemid 27400526)
28. Wilson SE, Mohan RR, Mohan RR, et al. The corneal wound healing response: cytokine-mediated interaction of the epithelium, stroma, and inflammatory cells. Prog Retin Eye Res 2001;20:625-637. (Pubitemid 32695343)
29. Jester JV, Huang J, Petroll WM, et al. TGF beta induced myofibroblast differentiation of rabbit keratocytes requires synergistic TGF beta, PDGF and integrin signaling. Exp Eye Res 2002;75:645-657. (Pubitemid 36034629)
30. Wang HS, Chard T. The role of insulin like growth factor 1 and insulin like growth factor binding protein in the control of human fetal growth. J Endocrinol 1992;132:11-16.
31. Clemmons DR. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 2007;6:821-833. (Pubitemid 47500506)
32. Frenzel E, Neely KA, Walsh AW, et al. A new model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1998;39:2157-2164. (Pubitemid 28455086)
33. Valeria Canto SM, Gallo JE, Dodds RA, et al. A mouse model of PVR induced by dispase. Exp Eye Res 2002;77:491-504.
34. Li S, Tang S, Li W, et al. Experiment study of retinal ultrastructure after intravitreal FK506. Yan Ke Xue Bao 2004; 20:34-38.
35. Oh-i K, Keino H, Goto H, et al. Intravitreal injection of tacrolimus (FK506) suppresses ongoing experimental autoimmune uveoretinitis in rats. Br J Ophthalmol 2007;91:237-242. (Pubitemid 46202878)
36. Fastenberg DM, Diddie KR, Sorgente N, et al. A comparison of different cellular inocula in an experimental model of massive periretinal proliferation. Am J Ophthalmol 1982;93: 559-564. (Pubitemid 12107404)
37. Dongqing Z, Hui C, Xun X. Effects of intravitreal dispase on vitreoretinal interface in rabbits. Curr Eye Res 2006;31: 935-946.
38. Stern WH, Guerin CJ, Erickson PA, et al. Ocular toxicity of fluorouracil after vitrectomy. Am J Ophthalmol 1983;96:43-51. (Pubitemid 13073320)
39. Steinhorst UH, Hatchell DL, Chen EP, et al. Ocular toxicity of daunomycin: effects of subdivided doses on the rabbit retina after vitreous gas compression. Graefes Arch Clin Exp Ophthalmol 1993;231:591-594. (Pubitemid 23338325)
40. Imai K, Loevvenstein A, Koroma B, et al. Herbimycin A in the treatment of experimental proliferative vitreoretinopathy: toxicity and efficacy studies. Graefes Arch Clin Exp Ophthalmol 2000;238:440-447. (Pubitemid 30342665)
41. Gummert JF, Ikonen T, Morris RE. Newer immunosuppressive drugs: a review. J Am Soc Nephrol 1999;10:1366-1380. (Pubitemid 29247004)
42. Jensik SC. Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group. Transplant Proc 1998;30:1216-1218. (Pubitemid 28309546)
43. Takamatsu H, Tsukada H, Noda A, et al. FK506 attenuates early ischemic neuronal death in a monkey model of stroke. J Nucl Med 2001;42:1833-1840. (Pubitemid 34016354)
44. Beck LA. The efficacy and safety of tacrolimus ointment: a clinical review. J Am Acad Dermatol 2005;53:165-170.
45. Koga T, Yano T, Ichikawa Y, et al. Pulmonary infiltrates recovered by FK506 in a patient with Behxcet's disease. Chest 1993;104:309-311. (Pubitemid 23204585)
46. Sakane T, Mochizuki M, Inaba G, et al. A phase II trial of FK 506 (tacrolimus) on refractory uveitis associated with Behxcet's disease and allied conditions. Ryumachi 1995;35:802-813.
47. Tano Y, Chandler D, McCuen BW, et al. Glucocorticoid inhibition of intraocular proliferation after injury. Am J Ophthalmol 1981;91:184-189. (Pubitemid 11184478)
48. Chandler DB, Rozakis G, de Juan E Jr, et al. The effect of triamcinolone acetonide on a refine experimental model of pro-liferative vitreoretinopathy. Am J Ophthalmol 1985;99:686-690. (Pubitemid 15059943)
49. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 1980;90:810-816. (Pubitemid 11199134)
50. Chandler DB, Hida T, Sheta S, et al. Improvement in efficacy of corticosteroid therapy in an animal model of proliferative vitreoretinopathy by pretreatment. Graefes Arch Clin Exp Ophthalmol 1987;225:259-265. (Pubitemid 17092217)
51. Blumenkranz MS, Ophir A, Glaflin AJ, et al. Fluoro-uracil for the treatment of massive perineu'rial proliferation. Am J Ophthalmol 1982;94:458-467. (Pubitemid 12032504)
52. Joondeph BC, Peyman GA, Khoobehi B, et al. Liposome-encapsulated 5-fluorouracil in the treatment of proliferative vitreoretinopathy. Ophthalmic Surg 1988;19:252-256.
53. Arroyo MH, Refojo MH, Araiz JJ, et al. Silicone oil as a delivery vehicle for BCNU in rabbit proliferative vitreor-etinopathy. Retina 1993;13:245-250. (Pubitemid 23285189)
54. Yoo JS, Sakamoto T, Spee C, et al. Cishydroxyproline inhibits proliferation, collagen synthesis, attachment and migration of cultured bovine retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 1997;38:520-528. (Pubitemid 27085709)
55. Lemor M, Yeo JH, Glaser BM. Oral colchicine for the treatment of experimental traction retinal detachment. Arch Ophthalmol 1986;8:1226-1229. (Pubitemid 16033930)
56. Richter A, Davies DE, Alexander P. Growth inhibitory effects of FK506 and cyclosporin A independent of inhibition of calcineurin. Biochem Pharmacol 1995;49:367-373.
57. Hamar P, Peti-Peterdi J, Szabó A, et al. Interleukin-2-dependent mechanisms are involved in the development of glomerulosclerosis after partial renal ablation in rats. Exp Nephrol 2001;9:133-141. (Pubitemid 32041491)
58. Nagano J, Iyonaga K, Kawamura K, et al. Use of tacrolimus, a potent antifibrotic agent, in bleomycin-induced lung fibrosis. Eur Respir J 2006;27:460-469. (Pubitemid 43372519)
59. Jain S, Bicknell GR, Nicholson ML. Tacrolimus has less fibrogenic potential than cyclosporin A in a model of renal ischaemia-reperfusion injury. Br J Surg 2000;87: 1563-1568.
60. Miyasaka N, Kawai S, Hashimoto H. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled doubleblind multicenter study. Mod Rheumatol 2009;19:606-615.
61. Mok CC, Tong KH, To CH, et al. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int 2005;68:813-817. (Pubitemid 43323138)